TG Therapeutics (TGTX) risk factors

Item 1A of every TG Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open TGTX in Gloom →

TG Therapeutics' chart, financials and news, free in your browser.Open TGTX in Gloom →

FY2025 10-K risk factors
75 risks1 new3 dropped21 reworded
TG Therapeutics added a specific risk regarding the development of a subcutaneous formulation of BRIUMVI. The company dropped risks covering broad market acceptance of BRIUMVI, third-party manufacturing reviews, and strategic resource allocation. Reworded risks updated details on tax capitalization rules for R&D and climate-related operational disruptions.
Filed Feb 27, 2026
FY2024 10-K risk factors
77 risks
TG Therapeutics relies heavily on the commercial success of its single marketed product, BRIUMVI, for multiple sclerosis.
Filed Mar 03, 2025